Zepbound – Talk Bio

Structure Therapeutics’ oral obesity drug shows competitive early data vs Novo and Lilly; Ascletis reports early obesity results

2 days ago talkbio0Tagged ASC41, Ascletis, eli lilly, Glucagon-Like Peptide 1, GSBR-1290, Obesity, Oral cavity, Ozempic, Phase 2 trial, safety profile, Structure Therapeutics, Wegovy, Weight Loss, Weight-Loss Agents, Zepbound

Structure Therapeutics; GSBR-1290; oral GLP-1; obesity pill; weight-loss drug; Novo Nordisk; Eli Lilly; Wegovy; Ozempic; Zepbound; Ascletis; ASC41; ASC42; phase 1 trial; phase 2 trial; weight reduction; safety profile

Lilly Slightly Lowers Self-Pay Prices for Single-Dose Vials of Zepbound

1 week ago talkbio0Tagged Direct-to-Consumer, eli lilly, Glucagon-Like Peptide 1, LillyDirect, Obesity Drug, price cut, Self-pay, single-dose vials, Zepbound

Eli Lilly; Zepbound; price cut; self-pay; single-dose vials; direct-to-consumer; LillyDirect; obesity drug; GLP-1

Eli Lilly Becomes First Drugmaker to Reach $1 Trillion Valuation

3 weeks ago talkbio0Tagged Capitalization, Drug Industry, eli lilly, Glucagon-Like Peptide 1, Market, Mounjaro, valuation, Weight-Loss Agents, Zepbound

Eli Lilly; trillion-dollar valuation; weight-loss drugs; Mounjaro; Zepbound; GLP-1 market; pharmaceutical industry; stock market; market capitalization

Trump Announces Sweeping Cost Cuts on Lilly and Novo Weight Loss Drugs in Exchange for Medicare Coverage

1 month ago talkbio0Tagged drug price, Eli Lilly ; Novo Nordisk, Glucagon-Like Peptide 1, Medicaid, Medicare, Prices, Transplant Registry Unified Management Program, Wegovy, Weight-Loss Agents, Zepbound

Trump; Eli Lilly; Novo Nordisk; weight loss drugs; GLP-1; Medicare; Medicaid; Wegovy; Zepbound; price cuts; drug pricing deal

Lilly and Novo Nordisk Near White House Deal to Cut Obesity Drug Prices

1 month ago talkbio0Tagged drug price, Eli Lilly, Glucagon-Like Peptide 1, Medicare coverage, Novo Nordisk, Obesity, Trump administration, Wegovy, White House, Zepbound

Lilly; Novo Nordisk; White House; obesity drug prices; Medicare coverage; GLP-1 medications; Trump administration; Zepbound; Wegovy

Friday Five: Lilly Expands Zepbound’s DTC Reach, NVIDIA Powers Drug Discovery at Lilly and Verily, and OpenAI Advances Pharma AI Initiatives

1 month ago talkbio0Tagged AI supercomputer, direct-to-consumer ( DTC ), Drug Discovery, federated learning, LillyDirect, NVIDIA, OpenAI, Pharma AI, TuneLab, Walmart partnership, Zepbound

LillyDirect; Zepbound; Direct-to-consumer (DTC); NVIDIA; AI supercomputer; Verily; OpenAI; Pharma AI; Drug discovery; Walmart partnership; TuneLab; Federated learning

More Than a Third of New Zepbound Prescriptions Driven by Lilly’s DTC Program

1 month ago talkbio0Tagged Direct-to-Consumer, discount, eli lilly, Glucagon-Like Peptide 1, Growth, LillyDirect, Market, Pricing, Sales - occupational activity, Sharing (Social Behavior), Walmart Pharmacy, Weight maintenance regimen, Zepbound

Zepbound; Eli Lilly; LillyDirect; direct-to-consumer; Walmart Pharmacy; GLP-1; weight management; discount pricing; market share; sales growth

Eli Lilly Blows Past Revenue Benchmarks, Again Raises Full-Year Outlook

1 month ago talkbio0Tagged earnings, eli lilly, exophthalmos producing substance, full-year guidance, Mounjaro, pharmaceutical innovation, Q3, revenue growth, Weight-Loss Agents, Zepbound

Eli Lilly; Q2 2025 earnings; Q3 2025 earnings; Mounjaro; Zepbound; weight-loss drugs; revenue growth; EPS; full-year guidance; pharmaceutical innovation